KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive

Myriam Alvarez3.33K FollowersFollow5ShareSavePlay(12min)CommentsSummaryKalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets.I think Ekterly’s convenience versus injectables supports future adoption. Repeat refills have also been a favorable tailwind.Looking ahead, Ekterly’s potential pediatric expansion into ages 2 to 11 could add meaningful upside.KALV intends to file that NDA by Q3 2026, and if approved, it would unlock an adjacent and untapped niche demographic.I believe KALV’s valuation still looks reasonable, especially after considering Ekterly is in its early growth stages. Thus, I reiterate my “Buy” rating at these levels. Bill Oxford/iStock via Getty Images KalVista Pharmaceuticals, Inc. (KALV) has Ekterly as its leading franchise for hereditary angioedema (HAE). This is an oral on-demand therapy, and it’s approved in seven markets for adults and children 12 years and older. KALV is alsoThis article was written byMyriam Alvarez3.33K FollowersFollowMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking Alpha. Our analyses are conducted independently, and we adhere to Seeking Alpha's Shared Association Guidelines.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.